
Schrodinger (SDGR) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
59.6M
Gross Profit
31.1M
52.26%
Operating Income
-50.9M
-85.45%
Net Income
-59.8M
-100.43%
EPS (Diluted)
$-0.82
Balance Sheet Metrics
Total Assets
743.0M
Total Liabilities
369.5M
Shareholders Equity
373.5M
Debt to Equity
0.99
Cash Flow Metrics
Operating Cash Flow
153.5M
Free Cash Flow
143.5M
Revenue & Profitability Trend
Schrodinger Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 207.5M | 216.7M | 181.0M | 137.9M | 108.1M |
Cost of Goods Sold | 75.5M | 76.0M | 79.9M | 72.3M | 44.6M |
Gross Profit | 132.1M | 140.7M | 101.0M | 65.6M | 63.5M |
Gross Margin % | 63.6% | 64.9% | 55.8% | 47.6% | 58.7% |
Operating Expenses | |||||
Research & Development | 201.8M | 181.8M | 126.4M | 90.9M | 64.7M |
Selling, General & Administrative | 139.6M | 136.4M | 121.5M | 86.2M | 59.7M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 341.4M | 318.1M | 247.8M | 177.1M | 124.4M |
Operating Income | -209.3M | -177.4M | -146.8M | -111.4M | -60.9M |
Operating Margin % | -100.8% | -81.9% | -81.1% | -80.8% | -56.4% |
Non-Operating Items | |||||
Interest Income | - | - | - | 1.1M | 2.3M |
Interest Expense | - | - | - | - | - |
Other Non-Operating Income | 23.6M | 220.4M | -2.3M | 10.6M | 34.6M |
Pre-tax Income | -185.7M | 42.9M | -149.1M | -100.8M | -26.3M |
Income Tax | 1.4M | 2.2M | 63.0K | 411.0K | 345.0K |
Effective Tax Rate % | 0.0% | 5.1% | 0.0% | 0.0% | 0.0% |
Net Income | -187.1M | 40.7M | -149.2M | -101.2M | -26.6M |
Net Margin % | -90.2% | 18.8% | -82.4% | -73.4% | -24.6% |
Key Metrics | |||||
EBITDA | -208.8M | -225.4M | -124.4M | -120.0M | -85.5M |
EPS (Basic) | $-2.57 | $0.57 | $-2.10 | $-1.42 | $-0.41 |
EPS (Diluted) | $-2.57 | $0.54 | $-2.10 | $-1.42 | $-0.41 |
Basic Shares Outstanding | 72670295 | 71776301 | 71173419 | 70594950 | 60024658 |
Diluted Shares Outstanding | 72670295 | 71776301 | 71173419 | 70594950 | 60024658 |
Income Statement Trend
Schrodinger Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 147.3M | 155.3M | 90.5M | 120.3M | 202.3M |
Short-term Investments | 204.8M | 307.7M | 360.6M | 456.2M | 440.4M |
Accounts Receivable | 235.7M | 66.0M | 56.0M | 31.7M | 31.4M |
Inventory | - | - | - | - | - |
Other Current Assets | - | - | - | - | - |
Total Current Assets | 635.0M | 567.8M | 534.0M | 625.1M | 683.0M |
Non-Current Assets | |||||
Property, Plant & Equipment | 122.8M | 127.1M | 106.1M | 75.4M | 10.1M |
Goodwill | 9.6M | 9.6M | 10.2M | 0 | - |
Intangible Assets | - | - | 587.0K | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 4.2M | 6.0M | 3.3M | 2.9M | 2.4M |
Total Non-Current Assets | 188.2M | 235.2M | 154.6M | 131.4M | 63.3M |
Total Assets | 823.2M | 803.0M | 688.6M | 756.5M | 746.3M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 10.7M | 16.8M | 9.5M | 8.1M | 8.4M |
Short-term Debt | 16.8M | 16.9M | 11.0M | 2.0M | 4.5M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 191.7M | 133.7M | 108.8M | 91.2M | 73.2M |
Non-Current Liabilities | |||||
Long-term Debt | 101.1M | 111.0M | 105.5M | 77.8M | 7.2M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 146.0K | 667.0K | 800.0K | 300.0K | 654.0K |
Total Non-Current Liabilities | 210.0M | 120.7M | 131.9M | 108.2M | 49.0M |
Total Liabilities | 401.8M | 254.4M | 240.7M | 199.4M | 122.2M |
Equity | |||||
Common Stock | 729.0K | 722.0K | 714.0K | 710.0K | 699.0K |
Retained Earnings | -525.5M | -338.4M | -379.1M | -230.0M | -129.6M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 421.4M | 548.6M | 447.9M | 557.1M | 624.0M |
Key Metrics | |||||
Total Debt | 117.8M | 127.9M | 116.5M | 79.9M | 11.8M |
Working Capital | 443.2M | 434.1M | 425.2M | 533.8M | 609.8M |
Balance Sheet Composition
Schrodinger Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -187.1M | 40.7M | -149.2M | -101.2M | -26.6M |
Depreciation & Amortization | 6.2M | 5.6M | 4.3M | 2.8M | 3.7M |
Stock-Based Compensation | 49.9M | 47.8M | 39.6M | 26.5M | 10.5M |
Working Capital Changes | -18.0M | -26.9M | -19.5M | -4.1M | 55.2M |
Operating Cash Flow | -149.0M | 67.2M | -124.7M | -75.2M | 44.9M |
Investing Activities | |||||
Capital Expenditures | -7.3M | -13.4M | -8.0M | -7.2M | -2.5M |
Acquisitions | 45.7M | 0 | -6.4M | 0 | -2.9M |
Investment Purchases | -251.3M | -324.7M | -272.1M | -418.5M | -519.7M |
Investment Sales | 361.8M | 384.0M | 364.7M | 408.5M | 138.8M |
Investing Cash Flow | 148.8M | 45.8M | 78.2M | -17.2M | -386.3M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | -58.0K | -19.0K | 0 | 0 | - |
Financing Cash Flow | 8.6M | -392.0K | 0 | 25.0K | 537.1M |
Free Cash Flow | -164.7M | -150.1M | -127.7M | -77.8M | 14.2M |
Net Change in Cash | 8.4M | 112.7M | -46.5M | -92.3M | 195.7M |
Cash Flow Trend
Schrodinger Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
44.39
Forward P/E
-8.12
Price to Book
4.30
Price to Sales
6.20
PEG Ratio
-2.19
Profitability Ratios
Profit Margin
-76.22%
Operating Margin
-96.61%
Return on Equity
-44.40%
Return on Assets
-17.52%
Financial Health
Current Ratio
3.30
Debt to Equity
33.38
Beta
1.68
Per Share Data
EPS (TTM)
$-2.48
Book Value per Share
$4.66
Revenue per Share
$3.26
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
sdgr | 1.5B | 44.39 | 4.30 | -44.40% | -76.22% | 33.38 |
Veeva Systems | 46.5B | 60.37 | 7.46 | 14.06% | 27.34% | 1.24 |
Ge Healthcare | 33.5B | 15.03 | 3.45 | 25.80% | 11.22% | 107.67 |
Certara | 1.8B | 223.60 | 1.68 | 0.75% | 1.97% | 29.00 |
10x Genomics | 1.7B | -8.79 | 2.17 | -11.30% | -13.13% | 11.22 |
GoodRx Holdings | 1.6B | 51.89 | 2.53 | 5.27% | 4.33% | 85.15 |
Financial data is updated regularly. All figures are in the company's reporting currency.